Connect with us

Technology

SimBioSys Achieves Second FDA Clearance for TumorSight™ Viz and Introduces TumorSight™ Clinical Decision Support for Breast Cancer Surgery

Published

on

CHICAGO, Nov. 4, 2024 /PRNewswire/ — SimBioSys®, a pioneering TechBio company at the forefront of digital precision medicine for cancer care, is proud to announce its second FDA 510(k) clearance for TumorSight™ Viz to expand its use by breast surgeons across the US. The updated TumorSight Viz now processes images with AI in a matter of minutes, integrates enhanced AI-driven tumor segmentation, enables seamless access to MRI images through direct connectivity to PACS systems, and has a first of its kind clinical decision support (CDS) feature that informs providers of evidence-based treatment options.  The addition of the CDS application is designed to enhance treatment planning and optimize oncologists’ decisions for early-stage breast cancer patients’ surgery.

With the recent FDA mandate which now requires breast density reporting for all women undergoing a mammogram, the demand for MRI as a supplementary screening tool is anticipated to rise. TumorSight Viz offers healthcare providers a powerful platform to visualize MRI data in 3D, supporting breast surgeons in tailoring treatment decisions to each patient’s unique tumor characteristics. The platform’s new CDS tool is designed to empower providers with advanced imaging insights and best practices for breast-conserving surgeries, aligning with updated NCCN guidelines promoting minimally invasive approaches when feasible and desired by patients.

“TumorSight Viz’s clinical decision support functionality provides a groundbreaking resource to assist breast surgeons and oncologists in considering the best possible approaches for each patient, fostering shared decision-making and precision care,” said Dr. Freya Schnabel from NYU.

TumorSight Viz: Key Enhancements

Enhanced AI-Driven Segmentation: Utilizing AI, TumorSight Viz is designed to deliver accurate and efficient tumor and tissue segmentation, enabling detailed 3D spatial visualization to support treatment planning.Clinical Decision Support (CDS) Application: The new CDS application is designed to provide data-driven insights for informing breast surgeons’ planning and preparation for surgeryDirect MRI Access via PACS Systems: TumorSight Viz now supports integration with middleware software as well as direct to PACS systems, allowing automated access to MRI images for analysis within the TumorSight platform and seamless fit into the clinician workflow.

Recent NCCN guideline updates emphasize the importance of individualized, data-supported treatment planning to support breast reconstruction and oncoplastic surgery as safe and effective options for eligible patients. TumorSight Viz aligns with these recommendations by enabling volume and anatomical measurements that assist surgeons in utilizing volume displacement techniques with a goal to achieve optimal cosmetic and functional outcomes. With the new CDS capability, surgeons are now better equipped with output measurements from TumorSight Viz that are aligned with standard of care guidelines to help plan lumpectomies more precisely, supporting both effective tumor removal and preservation of breast appearance.

A Game-Changer in Breast Cancer Care

Breast cancer affects more than 300,000 patients in the U.S. annually, many of whom now stand to benefit from SimBioSys’s enhanced TumorSight platform. By combining advanced AI-driven visualizations with CDS tools, TumorSight Viz is designed to provide surgeons, together with their patients, greater confidence in their treatment decisions.

“This second FDA clearance represents a significant milestone in our mission to redefine precision medicine for cancer,” said Barry Rosen, MD, Chief Medical Officer at SimBioSys. “TumorSight Viz’s latest capabilities elevate the standard of breast cancer care by allowing surgeons to make more informed choices, moving closer to an era of precision surgery that reduces variation and supports breast conservation when desired by the patient.”

TumorSight Viz is intended to be used in the visualization and analysis of breast magnetic resonance imaging (MRI) studies for patients with biopsy proven early-stage or locally advanced breast cancer.

About TumorSight™ Viz:
TumorSight™ Viz provides clinicians with 3D spatial visualizations of breast cancer using standard-of-care medical imaging (DCE MRI). Clear 3D “digital twin” renderings automatically display the tumor in the context of auto-segmented anatomical structures and provide key metrics used to inform the treatment planning process in conjunction with patient history and standard of care testing. TumorSight™ Viz received its original 510(k) FDA clearance in December 2023. Learn more about TumorSight Viz at https://simbiosys.com/tumorsight-viz.

About SimBioSys:
SimBioSys is a pioneering TechBio company leveraging artificial intelligence and computational modeling to harness the power of spatial biophysics to redefine precision medicine, transform patient care, and defeat cancer. By seeing cancer more completely, SimBioSys aims to empower clinicians and researchers with a more informed understanding of a patient’s tumor to optimally assess all available options and deliver on the promise of truly individualized patient care. To learn more, visit us at https://www.simbiosys.com/.

For media inquiries:
SimBioSys Marketing
media@simbiosys.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/simbiosys-achieves-second-fda-clearance-for-tumorsight-viz-and-introduces-tumorsight-clinical-decision-support-for-breast-cancer-surgery-302295938.html

SOURCE SimBioSys

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Sequel Brands Launches MOVE Powered by SEQUELai, the Company’s Sixth Brand and First Digital Wellness Platform

Published

on

By

MOVE closes the gap between knowing what to do and actually doing it with an AI coach designed for everyone – not just people who already exercise.

NEWPORT BEACH, Calif., July 20, 2026 /PRNewswire/ — Sequel Brands today announced the launch of MOVE powered by SEQUELai, the company’s sixth brand and first digital wellness platform. Joining a portfolio that includes Pilates Addiction, BODY20, iFlex Stretch Studios, Beem Light Sauna, and Ultimate Longevity Center, MOVE is available now on iOS and Android for $5/month or $25/year – a price point designed to make personalized wellness more accessible, regardless of fitness background. The platform combines AI-powered coaching, personalized workouts, recovery guidance, nutrition support, and daily accountability to help users build healthier routines that last.

Despite widespread awareness of healthy living, millions of Americans still struggle to consistently put healthy habits into practice. According to the CDC, fewer than half of U.S. adults meet federal guidelines for aerobic physical activity. MOVE was built to close that gap by making healthy movement simple, achievable, and sustainable – especially for those who don’t consider themselves “fitness people.”

Extending Sequel’s Mission Beyond the Studio

For Sequel Founder and CEO Anthony Geisler, who has spent his career building and scaling some of the industry’s most recognizable studio brands – from Club Pilates and Pure Barre to Sequel’s portfolio today – MOVE is the culmination of a belief he has championed for years: movement is the foundation of better health. Through industry stages, interviews, and podcasts – including his keynote at last year’s Athletech News Innovation Summit – Geisler has consistently argued that America’s health challenge isn’t a lack of information; it’s turning knowledge into consistent action.

“Movement is medicine – it’s the catalyst for all other health habits. Get a workout in, and a bowl of ice cream stops sounding like a good idea. Skip it, and the rest of the day tends to follow,” said Geisler. “The goal with MOVE is simple: more people moving more often, in more accessible ways.”

SmartCoach: AI That Adapts as You Do

At the heart of MOVE is SmartCoach, an AI-powered wellness coach that creates a personalized plan based on each member’s goals, fitness level, and schedule – then continuously learns and adapts as they progress. While most wellness apps are built for people who already exercise regularly, SmartCoach is designed for the millions who don’t, meeting users where they are and helping them build sustainable habits over time. Beyond personalized coaching, MOVE delivers programming across strength, cardio, mobility, recovery, sleep, meditation, nutrition, mental wellness, women’s health, GLP-1 companion support, and clinically informed musculoskeletal (MSK) recovery.

The platform will continue to evolve with new AI-powered experiences. Upcoming features include MePod, a personalized weekly podcast that recaps each member’s progress and prepares them for the week ahead, and Daily Recommendations, a dynamic workout feed that updates in real time based on how each person is actually training. Wearables integration follows, connecting with fitness trackers and health apps members are already using.

AI-Powered Innovation Across the Sequel Ecosystem

MOVE marks the beginning of Sequel’s broader AI strategy. The company is already developing the next generation of AI-powered member experiences designed to help people build healthier daily habits that drive long-term health and longevity, while giving franchisees new ways to improve retention, deepen member relationships, and drive more visits to their studios.

“Technology should make healthy living easier, not more overwhelming,” said Alex Isaly, Sequel Brands’ President of Platform and AI Strategy. “MOVE meets people where they are, with coaching that adapts as they do. This is the first step in Sequel’s broader AI strategy to turn education into execution – creating better experiences for members and unlocking new ways to support our growing wellness ecosystem.”

The MOVE Smarter, Live Brighter Challenge

To celebrate the launch, Sequel is introducing the MOVE Smarter, Live Brighter Challenge, starting July 20. Designed for every fitness level, participants complete four sessions each week – including walking, strength, mobility, and sleep – for a total of 16 guided sessions, while a live in-app tracker measures the community’s total minutes of movement in real time. No gym, equipment, or fitness background is required to get started.

To join the challenge, download MOVE powered by SEQUELai, available now on iOS and Android, or visit sequelbrands.com/move-challenge.

ABOUT SEQUEL BRANDS
Sequel Brands is a next-generation fitness franchisor redefining the future of movement, recovery, wellness, and longevity. With an experienced leadership team and a portfolio of high-growth concepts – including Pilates Addiction, iFlex Stretch Studios, Beem Light Sauna, BODY20, Ultimate Longevity Center, and MOVE Powered by SEQUELai – Sequel delivers a scalable platform built for lasting success, cultural impact, and real results in how people move, recover, and optimize their longevity. For more information, visit sequelbrands.com

MEDIA CONTACTS
Sequel Brands Communications
E: communications@sequelbrands.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/sequel-brands-launches-move-powered-by-sequelai-the-companys-sixth-brand-and-first-digital-wellness-platform-302830078.html

SOURCE Sequel Brands

Continue Reading

Technology

B&R Technology Merger Corp. Announces Pricing of $325 Million Initial Public Offering

Published

on

By

NEW YORK, July 20, 2026 /PRNewswire/ — B&R Technology Merger Corp. (the “Company”) announced the pricing of its initial public offering of 32,500,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “BRTMU” commencing on July 21, 2026. Each unit consists of one Class A ordinary share of the Company and one-third of one warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share of the Company at an exercise price of $11.50 per share. Once the securities constituting the units begin separate trading, the Company expects that the Class A ordinary shares and warrants will be listed on Nasdaq under the symbols ” BRTM” and ” BRTMW,” respectively.

The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any business or industry.

Citigroup Global Markets Inc. (“Citigroup”) is acting as sole bookrunner and representative of the underwriters. The Company has granted the underwriters a 45-day option to purchase up to 4,875,000 additional units at the initial public offering price to cover over-allotments, if any.

This offering will only be made by means of a prospectus. Copies of the preliminary prospectus relating to the offering and final prospectus, when available, may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by telephone at (800) 831-9146.

A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the Company’s offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

View original content:https://www.prnewswire.com/news-releases/br-technology-merger-corp-announces-pricing-of-325-million-initial-public-offering-302830053.html

SOURCE B&R Technology Merger Corp.

Continue Reading

Technology

Paris-Planet Is Back with a Fresh New Way to Explore Paris

Published

on

By

MONTREAL, July 20, 2026 /PRNewswire/ — Planning a trip to Paris just got a little easier.

Paris-Planet has officially relaunched with a completely redesigned website that helps travelers discover and book some of Paris’s best museums, attractions, tours, and local experiences in one place.

The new site was built for people who want to spend less time jumping between dozens of websites and more time getting excited about their trip. Whether it’s your first visit to Paris or your fifth, Paris-Planet brings together the experiences that make the city unforgettable.

“We wanted to build the kind of website we would actually use ourselves,” said Chaz Desousa, founder of Paris-Planet. “There are so many incredible things to see in Paris, but planning a trip can quickly become overwhelming. Our goal was to make discovering and booking experiences simple, inspiring, and enjoyable.”

Visitors can browse everything from famous landmarks and museums to food tours, river cruises, walking tours, family activities, and seasonal events. Along with tickets and experiences, the site also features destination guides, travel tips, and ideas for making the most of every day in Paris.

The relaunch also includes a faster website, improved navigation, and a mobile-friendly design, making it easy for travelers to plan before they leave home or while they’re already exploring the city.

Activity provider can sign up here to Sell Paris Tours & Tickets Online

Paris remains one of the world’s most visited destinations, welcoming millions of visitors every year. Paris-Planet was created to help those travelers spend less time searching and more time experiencing everything the city has to offer.

About Paris-Planet

Paris-Planet is an online travel guide and booking platform focused exclusively on Paris. The website helps visitors discover museums, attractions, tours, activities, and unique local experiences while making trip planning simple and enjoyable.

For more information, visit www.paris-planet.com.

View original content:https://www.prnewswire.com/news-releases/paris-planet-is-back-with-a-fresh-new-way-to-explore-paris-302829953.html

SOURCE Paris-Planet

Continue Reading

Trending